According to KFF Health News, Medicare Advantage prescription drug plans (MA‑PDs) now direct more than $600 in rebates per enrollee each year, over $50 per member per month, toward enhancements and premium reductions in 2026. That flow of rebate dollars has left most MA‑PD members in plans charging no premium for drug coverage. Meanwhile, stand‑alone prescription drug plan (PDP) sponsors, under greater cost pressure from the redesigned Part D benefit and the loss of some manufacturer rebates under Medicare’s drug price negotiation program, are temporarily supported by roughly $190 in annual premium subsidies per enrollee through the PDP Premium Stabilization Demonstration. The program lowers PDP premiums by about $16 each month. Federal law also caps annual growth in the Part D base beneficiary premium at 6%. Even with those efforts, the average PDP premium still stands far higher than MA‑PD premiums. And the average number of PDPs available per beneficiary has dropped to 11, compared with 32 MA‑PD options.
The structural imbalance stands out. MA‑PDs can use rebate‑funded buydowns to make drug coverage seem cheaper, while PDPs depend on short‑term federal support that can’t match the same rebate scale. The likely result, continued erosion of the stand‑alone PDP market as beneficiaries move toward MA‑PDs offering zero‑premium drug coverage. For payers and plan sponsors, that built‑in financial tilt within Medicare Advantage’s payment structure could drive further consolidation and squeeze PDP competition, even with premium caps tempering visible rate increases. Analysts will be watching whether CMS extends or expands the PDP stabilization initiative once current subsidies end. The rebate gap, after all, remains. And if nothing shifts, the PDP market’s decline may simply settle into place, confirming MA‑PDs’ hold on Part D coverage.
